Anzeige
Mehr »
Donnerstag, 07.08.2025 - Börsentäglich über 12.000 News
Große CEO-Enthüllung: Analysten sehen +56% Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLX7 | ISIN: US10806X1028 | Ticker-Symbol: 2CL
Tradegate
07.08.25 | 09:31
38,860 Euro
+1,20 % +0,460
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
BRIDGEBIO PHARMA INC Chart 1 Jahr
5-Tage-Chart
BRIDGEBIO PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
38,18038,94010:24
38,18038,94010:24

Aktuelle News zur BRIDGEBIO PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiBridgeBio Pharma stock rating reiterated at Buy by TD Cowen on strong Attruby sales3
BRIDGEBIO PHARMA Aktie jetzt für 0€ handeln
MiBridgeBio Pharma: TD Cowen bestätigt Kaufempfehlung dank starker Attruby-Umsätze9
MiNxera debuts an obesity pipeline; BridgeBio battles Alynam for market share13
MiHelix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics166Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing2nd lowest redemption rate...
► Artikel lesen
MiBridgeBio Pharma stock price target raised to $61 by Oppenheimer8
DiBridgeBio Pharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans23
DiBridgeBio Pharma, Inc.: BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates132- As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial...
► Artikel lesen
29.07.Raymond James assumes coverage on BridgeBio stock with Outperform rating12
29.07.Cantor Fitzgerald maintains BridgeBio stock rating, sees $3B+ potential7
23.07.BridgeBio Pharma, Inc.: Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1184- By examining over 100 unique variants associated with the CASR gene causative of ADH1, the average frequency of gain-of-function CASR variants was ~3.7 per 100,000, closely aligned to previously...
► Artikel lesen
21.07.BridgeBio stock initiated with Buy rating at Truist on strong Attruby launch7
18.07.BridgeBio Pharma stock maintains Buy rating at H.C. Wainwright after royalty deal10
14.07.Citi reiterates Buy rating on BridgeBio stock ahead of key trial data28
14.07.BridgeBio Pharma stock initiated with Buy rating at Jefferies on Attruby potential9
14.07.Jefferies stuft BridgeBio Pharma mit "Buy" ein - Milliardenpotenzial bei Herzmedikament Attruby18
11.07.Helix Acquisition Corp. II shareholders to vote on BridgeBio Oncology merger on August 420
03.07.BridgeBio Pharma-Aktie: Overweight-Rating von Cantor Fitzgerald bestätigt41
03.07.BridgeBio Pharma stock rating reiterated at Overweight by Cantor Fitzgerald1
02.07.BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights2
30.06.BridgeBio Pharma stock supported by Raymond James after $300M royalty deal8
Weiter >>
125 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1